We further defined a critical role for PML in the maintenance of leukemia-initiating cells (LICs) in disease models of chronic myeloid leukemia (CML), and presented a new therapeutic approach based on targeting quiescent LICs by pharmacological inhibition of PML. Here, PML is linked to chronic myelogenous leukemia, BCR-ABL1 positive.